絞り込み

16645

広告

新型ウイルス肺炎 患者440人 死者9人 重症102人 医師も感染か

中国で感染が拡大する新型のコロナウイルスによるとみられる肺炎について中国政府は、患者は440人に増え、死者は9人、症状が重い患者は102人に上ると発表しました。...

  1. 新型ウイルス肺炎 タイで新たに2人感染 ...
  2. 【質疑詳報】新型ウイルス肺炎 中国政府が...
  3. トリチウム含む水の処分“ほかの選択肢検討...
  4. 新型ウイルス肺炎「感染源は市場の野生動物...

ニュース一覧

Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial.

著者 Shakur-Still H , Roberts I , Fawole B , Kuti M , Olayemi OO , Bello A , Huque S , Ogunbode O , Kotila T , Aimakhu C , Okunade OA , Olutogun T , Adetayo CO , Dallaku K , Mansmann U , Hunt BJ , Pepple T , Balogun E
Wellcome Open Res.2018 ; 3():100.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Postpartum haemorrhage (PPH) is a leading cause of maternal death. The WOMAN trial showed that tranexamic acid (TXA) reduces death due to bleeding in women with PPH. We evaluated the effect of TXA on fibrinolysis and coagulation in a sample of WOMAN trial participants. Adult women with a clinical diagnosis of PPH were randomised to receive 1 g TXA or matching placebo in the WOMAN trial. Participants in the WOMAN trial at University College Hospital (Ibadan, Nigeria) also had venous blood taken just before administration of the first dose of trial treatment and again 30 (±15) min after the first dose (the ETAC study).  We aimed to determine the effects of TXA on fibrinolysis (D-dimer and rotational thromboelastometry maximum clot lysis (ML)) and coagulation (international normalized ratio and clot amplitude at 5 min). We compared outcomes in women receiving TXA and placebo using linear regression, adjusting for baseline measurements. Women (n=167) were randomised to receive TXA (n=83) or matching placebo (n=84). Due to missing data, seven women were excluded from analysis. The mean (SD) D-dimer concentration was 7.1 (7.0) mg/l in TXA-treated women and 9.6 (8.6) mg/l in placebo-treated women (p=0.09). After adjusting for baseline, the D-dimer concentration was 2.16 mg/l lower in TXA-treated women (-2.16, 95% CI -4.31 to 0.00, p=0.05). There was no significant difference in ML between TXA- and placebo-treated women (12.3% (18.4) and 10.7% (12.6), respectively; p=0.52) and no significant difference after adjusting for baseline ML (1.02, 95% CI -3.72 to 5.77, p=0.67).  There were no significant effects of TXA on any other parameters. TXA treatment was associated with reduced D-dimer levels but had no apparent effects on thromboelastometry parameters or coagulation tests. ISRCTN76912190 (initially registered 10/12/2008, WOMAN-ETAC included on 22/03/2012) and NCT00872469 (initially registered 31/03/2009, WOMAN-ETAC included on 22/03/2012).
PMID: 30345385 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード